Lonza Signs Deal with Swedish Start-up

Lonza says it has signed a deal to provide development and cGMP manufacturing services for Athera (Solna, Sweden), a start-up biotech company. Financial terms were not disclosed. Athera is part of Karolinska Development (Solna), a group which has a portfolio of more than 40 pharmaceutical companies.   Lonza says it will initiate cell line and process development, using its GS Gene expression system for Athera’s monoclonal antibody, PC-mAb, a developmental drug intended for the treatment of patients with acute coronary syndrome (ACS). People with ACS...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers